Form 4: Vor Biopharma Executive Chakraborty Reports Stock Option Repricing and RSU Grant

Tirtha Chakraborty, Chief Scientific Officer of Vor Biopharma, reports a stock option repricing and the acquisition of restricted stock units (RSUs) on February 3, 2025.

Summary

• On February 3, 2025, Tirtha Chakraborty, the Chief Scientific Officer of Vor Biopharma, reported transactions related to the company's stock.
• These transactions include the withholding of 1,163 shares to cover tax obligations related to the settlement of restricted stock units (RSUs) at a price of $1.34.
• Chakraborty also acquired 52,500 shares underlying RSUs, which vest in equal quarterly installments over four years starting February 1, 2025.
• Additionally, a stock option award repricing was approved by the Board of Directors, effective February 3, 2025, adjusting the exercise price of several employee stock options to $1.34 per share, representing the fair market value on that date.
• The repriced stock options may revert to their original exercise price if exercised during a 12-month Retention Period, or upon a Change in Control, or 30 days prior to the option's original expiration date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The repricing and RSU grant suggest a continued investment in the executive team. The terms of the repricing are fairly standard.

Positives

• The stock option repricing could incentivize Chakraborty and other employees by aligning their interests with the company's current stock value.
• The granting of RSUs provides Chakraborty with additional equity in the company, further aligning his interests with shareholders.
• The vesting schedule of the RSUs (quarterly over four years) encourages long-term commitment from Chakraborty.

Risks

• The repriced stock options could revert to their original, potentially higher, exercise price if exercised within the Retention Period, which could disincentivize early exercise.
• The value of the RSUs is subject to the volatility of Vor Biopharma's stock price.

Future Outlook

The vesting of RSUs and exercisability of stock options are contingent upon Chakraborty's continued service with Vor Biopharma.

Industry Context

Stock option repricing and RSU grants are common practices in the biopharmaceutical industry to incentivize and retain key executives, especially in companies focused on long-term research and development.

Comparison to Industry Standards

• Stock option repricing is a relatively common practice, particularly in volatile markets, to maintain the incentive value of options.
• RSU grants are also standard practice, with vesting schedules typically ranging from three to five years, similar to the four-year vesting schedule described in the document.
• Comparable companies like CRISPR Therapeutics or Editas Medicine also utilize stock options and RSU grants as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option repricing and RSU grants as a positive sign, indicating the company's commitment to retaining key talent.
• Employees, particularly those holding stock options, may benefit from the repricing, as it makes their options more valuable.
• The repricing and RSU grants have no immediate impact on customers, suppliers, or creditors.

Key Dates

Keywords

Vor Biopharma, Chakraborty, Stock Option, Repricing, RSU, Equity, Beneficial Ownership, Form 4